Oligonucleotide Delivery System Market Size, Share & Trends Analysis Distribution by Delivery System (Conjugation-Based Delivery Systems (GALNAc Conjugation, Ligand Conjugation, Antibody Conjugation, Targeting Moiety Conjugation), Nanoparticle-Based Delivery Systems (Lipid Nanoparticles (LNPs), Peptide Nanoparticles), Viral Vector-Based Delivery Systems (Adeno-associated Virus (AAV) Vectors, AAV9, Lentiviral Vectors, Others), Exosome-Based Delivery Systems, Liposomes, Others), Disease Indication and Segment Forecasts, 2024-2031

Report Id: 2779 Pages: 165 Last Updated: 20 September 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Oligonucleotide Delivery System Market

Oligonucleotide Delivery System Market by Delivery System

  • Conjugation-Based Delivery Systems
    • GALNAc Conjugation
    • Ligand Conjugation
    • Antibody Conjugation
    • Targeting Moiety Conjugation
  • Nanoparticle-Based Delivery Systems
    • Lipid Nanoparticles (LNPs)
    • Peptide Nanoparticles
  • Viral Vector-Based Delivery Systems
    • Adeno-associated Virus (AAV) Vectors
    • AAV9
    • Lentiviral Vectors
    • Others
  • Exosome-Based Delivery Systems
  • Liposomes
  • Others

oligonucleotide

Oligonucleotide Delivery System Market by Disease Indication

  • Genetic Disorders
  • Infectious Diseases
  • Oncology
  • Neurological Disorders
  • Others (Autoimmune Diseases, Metabolic Disorders, etc.)

Oligonucleotide Delivery System Market by Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Oligonucleotide Delivery System Market Snapshot

Chapter 4. Global Oligonucleotide Delivery System Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Oligonucleotide Delivery System Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Oligonucleotide Delivery System Industry Trends

Chapter 5. Oligonucleotide Delivery System Market Segmentation 1: By Delivery System, Estimates & Trend Analysis
5.1. Market Share by Delivery System, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Delivery System:

5.2.1. Conjugation-Based Delivery Systems

5.2.1.1. GALNAc Conjugation
5.2.1.2. Ligand Conjugation
5.2.1.3. Antibody Conjugation
5.2.1.4. Targeting Moiety Conjugation

5.2.2. Nanoparticle-Based Delivery Systems

5.2.2.1. Lipid Nanoparticles (LNPs)
5.2.2.2. Peptide Nanoparticles

5.2.3. Viral Vector-Based Delivery Systems

5.2.3.1. Adeno-associated Virus (AAV) Vectors
5.2.3.2. AAV9
5.2.3.3. Lentiviral Vectors
5.2.3.4. Others

5.2.4. Exosome-Based Delivery Systems
5.2.5. Liposomes
5.2.6. Others

Chapter 6. Oligonucleotide Delivery System Market Segmentation 2: By Disease Indication, Estimates & Trend Analysis
6.1. Market Share by Disease Indication, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Disease Indications:

6.2.1. Genetic Disorders
6.2.2. Infectious Diseases
6.2.3. Oncology
6.2.4. Neurological Disorders
6.2.5. Others (Autoimmune Diseases, Metabolic Disorders, etc.)

Chapter 7. Oligonucleotide Delivery System Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global Oligonucleotide Delivery System Market, Regional Snapshot 2023 & 2031

7.2. North America
7.2.1. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

7.2.1.1. US
7.2.1.2. Canada

7.2.2. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.2.3. North America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031

7.3. Europe
7.3.1. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe

7.3.2. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.3.3. Europe Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031

7.4. Asia Pacific
7.4.1. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific

7.4.2. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.4.3. Asia Pacific Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031

7.5. Latin America
7.5.1. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America

7.5.2. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.5.3. Latin America Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031

7.6. Middle East & Africa
7.6.1. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa

7.6.2. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2024-2031
7.6.3. Middle East & Africa Oligonucleotide Delivery System Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2031

Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles

8.2.1. Biogen
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Offerings
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Sarepta Therapeutics, Inc.
8.2.3. Jazz Pharmaceuticals plc
8.2.4. Ionis Pharmaceuticals, Inc.
8.2.5. Nippon Shinyaku Co., Ltd.
8.2.6. AstraZeneca
8.2.7. Alnylam Pharmaceuticals, Inc.
8.2.8. Novartis AG
8.2.9. Dicerna Pharmaceuticals, Inc. (Novo Nordisk)
8.2.10. IVERIC bio, Inc. (Astellas Pharma Inc.)
8.2.11. Elsie Biotechnologies (GSK)
8.2.12. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5171
Security Code field cannot be blank!

Frequently Asked Questions

The Oligonucleotide Delivery System Market is predicted to grow at an 12.4% CAGR during the forecast period for 2024-2031.

Biogen, Sarepta Therapeutics, Inc., Jazz Pharmaceuticals plc, Ionis Pharmaceuticals, Inc., Nippon Shinyaku Co., Ltd., AstraZeneca, Alnylam Pharmaceuti

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying